CSPC Pharmaceutical's interim profit rises 2.4 times

サーチナ··CN·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

CSPC Pharmaceutical announced that its interim profit increased 2.4 times compared with the same period last year. The rise was mainly driven by higher licensing fee income, reflecting an improvement in the company's earnings structure. Detailed figures and the reporting period were not disclosed, but a substantial profit expansion in the interim results was confirmed.

Impact on assets 1

Biotech & Genomic Medicine▲ · 1 stocks
© 2026 MarketIVNews